John W. Kaveney, a partner in the firm’s Healthcare and Litigation Departments, will present the program “The Conclusion of the Public Health Emergencies: What This Means for Healthcare Providers and the Accommodations Put in Place by the Federal and State Governments” at the New Jersey & Metro Philadelphia HFMA 47th Anniversary Annual Institute. The
During the COVID-19 pandemic, the federal government and many state governments went to great lengths to relax many of the restrictions on telehealth that had historically limited this medium in the provision of healthcare services to patients. However, in an effort to ensure that patients could continue to access necessary healthcare during this time period
As recently reported by HealthITSecurity, IBM Security’s 2023 Cost of a Data Breach Report revealed that the average cost of a healthcare data breach was almost $11 million in 2022, an $800,000 increase from the prior year and a 53% increase from 2020. The report further revealed that the global average cost of a
On June 15, 2023, the Medicare Payment Advisory Commission (MedPAC), a nonpartisan independent legislative branch agency that was created to advise Congress on a range of issues affecting Medicare, issued its 2023 Report to Congress. Included therein was a report, mandated by the Consolidated Appropriations Act, on the usage of telehealth services during the public
The U.S. Department of Health & Human Services Office of Civil Rights (OCR) announced on April 11, 2023 that the Notifications of Enforcement Discretions issued during the COVID-19 Public Health Emergency (PHE) would be expiring at 11:59 p.m. on May 11, 2023 due to the expiration of the PHE. A copy of the notice of
In August 2022, President Biden signed into law the Inflation Reduction Act. The Act’s key provisions include the ability of the federal government to negotiate certain prescription drug pricing. Specifically, the law created a program that allows the federal government to negotiate prices for a limited number of high-cost single-source drugs (lacking generic and/or biosimilar
In light of the New Jersey Appellate Division’s recent decision in County of Passaic v. Horizon Healthcare Services affirming the validity of a commercial arbitration agreement that did not contain a jury waiver, contracting entities including those in the healthcare sector need to approach language differently depending on whether they are dealing with a consumer
On February 10, 2023, the United States National Security Agency (NSA), the U.S. Federal Bureau of Investigation (FBI), the U.S. Cybersecurity and Infrastructure Security Agency (CISA), the U.S. Department of Health and Human Services (HHS), the Republic of Korea (ROK) National Intelligence Service (NIS), and the ROK Defense Security Agency (DSA) issued a joint Cybersecurity
Providers practicing in New York State who are enrolled in Medicaid should strongly consider revisiting their compliance programs following the recent issuance of new requirements by the New York State Office of the Medical Inspector General (OMIG).
On December 28, 2022, the OMIG issued new regulations (18 NYCRR 521-1.1, et seq.) requiring Medicaid-enrolled providers practicing
As discussed in this prior blog post, beginning in 2018 the U.S. Department of Health and Human Services (HHS) reduced reimbursement rates for Medicare prescription drugs to 340B hospitals by nearly thirty percent. The American Hospital Association (AHA) filed suit, and on June 15, 2022 the U.S. Supreme Court ruled that the cuts imposed